Biopharmx corp (BPMX)
Income statement / Quarterly
Jan'20Oct'19Jul'19Apr'19Jan'19Oct'18Jul'18Apr'18Jan'18Oct'17Jul'17Apr'17Jan'17Oct'16Jul'16Apr'16Jan'16Oct'15Jul'15Apr'15Dec'14Sep'14Jul'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Dec'10
Revenues, net

-

-

-

-

5

10

24

18

-

18

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cost of goods sold

-

-

-

-

3

60

13

7

-

8

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Revenues, net

-

-

-

-

-

-

-

-

-

-

17

19

15

33

19

33

35

20

5

4

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cost of goods sold

-

-

-

-

-

-

-

-

-

-

9

11

451

28

17

20

199

19

10

9

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gross margin

-

-

-

-

2

-50

11

11

-203

10

8

8

-436

5

2

13

-164

1

-5

-5

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

REVENUES

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

0

0

0

0

Operating expenses:
Research and development

376

740

1,375

2,199

1,794

2,228

2,730

2,327

1,675

2,111

2,413

2,941

2,525

2,487

2,973

2,173

1,836

1,649

1,141

1,076

668

807

623

657

387

271

221

148

31

-

-

-

-

-

-

-

-

-

Sales and marketing

142

139

169

264

440

550

566

601

486

546

586

797

667

529

895

1,107

1,451

1,270

1,307

1,081

962

757

435

367

213

59

48

12

13

-

-

-

-

-

-

-

-

-

Professional fees

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

45

1

2

2

19

1

5

1

52

1

1

1

General and administrative

748

1,241

1,116

1,177

992

1,624

1,182

1,446

1,473

1,088

1,280

1,303

1,138

1,154

1,169

1,193

1,100

930

1,118

1,026

1,153

515

732

802

483

405

160

87

59

0

0

0

0

0

0

0

1

1

Total operating expenses

1,266

2,120

2,660

3,640

3,226

4,402

4,478

4,374

3,634

3,745

4,279

5,041

4,330

4,170

5,037

4,473

4,387

3,849

3,566

3,183

2,783

2,079

1,790

1,826

1,083

735

429

247

103

2

19

1

5

1

53

1

2

2

Interest Income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

0

0

0

-

-

-

-

Loss from operations

-1,266

-2,120

-2,660

-3,640

-3,224

-4,452

-4,467

-4,363

-3,837

-3,735

-4,271

-5,033

-4,766

-4,165

-5,035

-4,460

-4,551

-3,848

-3,571

-3,188

-

-2,079

-1,790

-1,826

-

-835

-429

-247

-2

-2

-19

-1

-5

-1

-53

-1

-2

-2

Change in fair value of warrant liability

-

0

2

9

-

42

23

-66

34

169

525

-364

-

334

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other income (expense), net

-319

7

12

10

-861

20

34

29

16

-148

5

1

-96

-47

1

1

0

0

0

-436

-

-

14

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss before provision for income taxes

-1,320

-2,113

-2,646

-3,621

-4,100

-4,390

-4,410

-4,400

-3,787

-3,714

-3,741

-5,396

-5,033

-3,878

-5,034

-4,459

-4,551

-3,848

-3,571

-3,624

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other income

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

16

-

15

-

-

0

0

-

-

-

-

-

-

-

-

-

-

Interest expense

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2

2

-

2

70

-

22

13

6

-

-

-

-

-

-

-

-

-

Provision for income taxes

0

0

0

2

0

0

0

2

1

0

0

1

0

0

0

2

-

2

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss and comprehensive loss

-1,305

-2,113

-2,646

-3,623

-4,056

-4,390

-4,410

-4,402

-3,788

-3,714

-3,741

-5,397

-5,033

-3,878

-5,034

-4,461

-4,553

-3,850

-3,571

-3,624

-2,776

-2,065

-1,776

-1,813

-1,153

-768

-451

-260

-109

-

-

-

-

-

-

-

-

-

Accretion on Series A convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

79

123

-

-

27

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deemed dividend on Series A convertible preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

85

116

-

-

45

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss available to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-4,553

-3,850

-3,735

-3,863

-

-

-1,848

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deemed dividend on Series A convertible redeemable preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-37

-

-33

-

-

0

0

-

-

-

-

-

-

-

-

-

-

Net loss available to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-2,102

-

-1,846

-1,083

-

-451

-260

-103

-2

-19

-1

-5

-1

-

-

-

-

Basic and diluted net loss per share

-0.01

-0.14

-0.22

-0.38

-0.47

-0.57

-0.58

-0.61

-0.01

-0.05

-0.05

-0.08

-0.05

-0.12

-0.18

-0.17

-0.14

-0.18

-0.24

-0.33

-0.29

-0.20

-0.18

-0.18

-0.13

-0.10

-0.06

-0.04

-0.02

0.00

0.00

0.00

0.00

0.00

-0.01

0.00

0.00

0.00

Shares used in computing basic and diluted net loss per share

15,334

14,672

12,245

9,433

8,412

7,654

7,653

7,189

121,914

79,659

74,357

67,670

57,095

31,253

28,674

26,202

23,579

21,037

15,443

11,741

-9,005,129

10,630

10,551

10,367

9,025,000

-7,368,949

7,025

7,400

7,383,000

-

-

-

-

-

-

-

-

-

WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING: BASIC AND DILUTED

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

9,000

9,000

9,000

9,000

9,000

9,000

9,000

9,000

9,177

9,000

7,666

7,000